Overview: Squamous Cell Carcinoma Antigen TestIntroduction: The Squamous Cell Carcinoma Antigen Test measures SCCA to diagnose squamous cell carcinoma, causing lumps or sores. Following 2023 NCCN guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected squamous cell carcinoma.
Other Names: SCCA Assay, Squamous Cell Antigen Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: SCCA testing began in the 1970s with cancer biomarker research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures SCCA to diagnose squamous cell carcinoma, guides treatment, and evaluates patients with lumps or sores.
Test Parameters: 1. SCCA Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of lumps, sores, or cancer symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document lumps, sores, or history of squamous cell carcinoma. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to measure SCCA levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for cancer diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Non-squamous cancers may not elevate SCCA.
Clinical Significance: Elevated SCCA confirms squamous cell carcinoma, guiding surgery or chemotherapy. Normal levels may require imaging or biopsy.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Biopsy, CT scan, or PET scan to confirm squamous cell carcinoma diagnosis.
Test Limitations: Non-specific for certain cancers; clinical correlation is needed. Sample quality affects sensitivity.
References: NCCN Cancer Guidelines, 2023; Journal of Clinical Oncology, Kato H, 2022.
